Failing Fontan following total cavopulmonary connection: extracardiac biomarkers reveal two distinct phenotypes with divergent clinical courses
Clicks: 3
ID: 322946
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
0.6
/100
3 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #46 of 87 articles by views in Interdisciplinary CardioVascular and Thoracic Surgery
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
OBJECTIVES: Failing Fontan is an increasingly recognised complication after total cavopulmonary connection, yet longitudinal biomarker data remain scarce. We aimed to characterise the incidence, biomarker trajectories, and prognostic determinants of failing Fontan. METHODS: All patients who underwent primary total cavopulmonary connection (n = 650) or conversion to total cavopulmonary connection (n = 19) at our centre between 1994 and 2022 were reviewed. Lymphocyte count, N-terminal pro-brain natriuretic peptide and its zlog value, and Fibrosis-4 index were assessed at 1 year before, 6 months before, at onset, and at last follow-up. Patients were classified into protein-losing enteropathy/plastic bronchitis and heart failure phenotypes. RESULTS: Failing Fontan developed in 78 primary total cavopulmonary connection patients (12.0%) and 12 conversion patients (63.2%). Conversion patients developed failing Fontan earlier (P < 0.001), but survival after onset survival was comparable. Lymphocyte counts declined before onset (2.49 to 0.89 ×10³/µL, P < 0.001) and Fibrosis-4 index increased (0.060 to 0.330, P < 0.001). Phenotypes showed divergent profiles: zlog-N-terminal pro-brain natriuretic peptide at onset was 0.71 in protein-losing enteropathy/plastic bronchitis versus 5.34 in heart failure (P < 0.001). Lymphocytopenia predicted mortality early (hazard ratio 6.77, P = 0.013) but appeared protective at last follow-up (hazard ratio 0.18, P = 0.049), reflecting a phenotypic shift. On multivariable analysis, lower lymphocyte count independently predicted mortality (hazard ratio 2.44, P = 0.041), while stent implantation was independently associated with lower mortality (hazard ratio 0.32, P = 0.040). CONCLUSIONS: Lymphocyte counts and Fibrosis-4 index change progressively before clinical onset and may serve as early warning biomarkers. The prognostic interpretation of lymphocytopenia depends on the underlying phenotype, underscoring the need for phenotype-aware monitoring.
| Reference Key |
openalex_W7171836478
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Muneaki Matsubara, Havva Aldogan, Thibault Schaeffer, Christina Ruda, Christoph Röhlig, Jonas Palm, Nicole Piber, Alfred Hager, Peter Ewert, Jürgen Hörer, Masamichi Ono |
| Journal | Interdisciplinary CardioVascular and Thoracic Surgery |
| Year | 2026 |
| DOI |
10.1093/icvts/ivag213
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.